Prosecution Insights
Last updated: May 29, 2026

Examiner: RAHMAN, MASUDUR

Tech Center 1600 • Art Units: 1623 1631 1633 1634 1699

This examiner grants 70% of resolved cases

Performance Statistics

70.5%
Allow Rate
+10.5% vs TC avg
138
Total Applications
+32.3%
Interview Lift
1448
Avg Prosecution Days
Based on 105 resolved cases, 2023–2026

Rejection Statute Breakdown

1.1%
§101 Eligibility
7.3%
§102 Novelty
68.7%
§103 Obviousness
10.6%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18010857 METHODS AND COMPOSITIONS FOR MODULATING CELLS AND CELLULAR MEMBRANES Non-Final OA FLAGSHIP PIONEERING INNOVATIONS VI, LLC
18034620 OVEREXPRESSION OF INSULIN-LIKE GROWTH FACTOR RECEPTOR MUTANTS TO MODULATE IGF SUPPLEMENTATION Non-Final OA AMGEN INC.
18283744 METHOD FOR PRODUCING PLURIPOTENT STEM CELL POPULATION Non-Final OA KANEKA CORPORATION
18271294 DRIED CELL SECRETOME-BASED THERAPEUTIC AGENT FOR OSTEOARTHRITIS TREATMENT Non-Final OA SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
17904106 METHODS FOR IMPROVED DELIVERY OF THERAPEUTIC AGENTS Final Rejection William Marsh Rice University
17748983 SPYCATCHER AND SPYTAG: UNIVERSAL IMMUNE RECEPTORS FOR T CELLS Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
18341811 HYPOTHERMIC OXYGENATED PERFUSION SOLUTION FOR REPAIRING KIDNEY INJURY AND USE THEREOF Non-Final OA WUHAN UNIVERSITY
16669191 COMPOSITIONS AND METHODS FOR TREATING CANCER Non-Final OA University of Virginia Patent Foundation
17601684 CELL Non-Final OA AUTOLUS LIMITED
18246250 STERILE ORGANISMS, METHODS OF MAKING, AND METHODS OF USE THEREOF Non-Final OA Brandeis University
17817125 PROCESSES FOR GENERATING SUPERIOR ANTI-TUMOR T-CELL EFFECTOR AND MEMORY CELLS Final Rejection MUSC Foundation for Research Development
18281412 COMPOSITION FOR PREVENTING OR TREATING DEGENERATIVE BRAIN DISEASES Non-Final OA KOLON LIFE SCIENCE, INC.
18280093 USE OF MESENCHYMAL STEM CELLS OVEREXPRESSING PACER FOR THE TREATMENT OF DISEASES WITH INFLAMMATORY ORIGIN AND/OR COMPONENT Non-Final OA Universidad del Desarrollo
18280103 METHOD OF MODIFYING GENOMIC DNA AND METHOD OF DETECTING MODIFICATION Non-Final OA Logomix, Inc.
18366306 IMMUNOSTIMULATORY OLIGONUCLEOTIDES Non-Final OA Elanco Animal Health GmbH
18082857 REGENERATIVE CAR-T CELLS Non-Final OA CREATIVE MEDICAL TECHNOLOGIES, INC.
18331956 METHOD FOR PREPARING TUMOR-DERIVED MICROPARTICLES BY MICROWAVE Non-Final OA Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
17292811 COMPOSITIONS AND METHODS FOR ADOPTIVE CELL THERAPY FOR CANCER Non-Final OA MEMORIAL SLOAN KETTERING CANCER CENTER
17788908 Inhibitor of Fertilized Egg Fragmentation Non-Final OA National Center for Child Health and Development
17775801 METHODS AND A KIT TO REPROGRAM SOMATIC CELLS Non-Final OA Atsuo Ochi
17599446 EX VIVO METHODS FOR PRODUCING A T CELL THERAPEUTIC AND RELATED COMPOSITIONS AND METHODS Final Rejection TURNSTONE BIOLOGICS CORP.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month